A Randomized, Placebo/Active Controlled, Single/Multiple Dosing, Dose Escalation Clinical Phase 1a/b Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients
Latest Information Update: 22 Feb 2023
At a glance
- Drugs CJ-15314 (Primary) ; Pimecrolimus
- Indications Atopic dermatitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors HK inno.N
- 22 Feb 2023 New trial record